Picoplatin: Difference between revisions
Content deleted Content added
m +cat |
Citation bot (talk | contribs) Add: pages, issue. Removed parameters. | Use this bot. Report bugs. | Suggested by Abductive | #UCB_webform 305/373 |
||
| (44 intermediate revisions by 29 users not shown) | |||
| Line 1: | Line 1: | ||
{{chembox |
|||
{{deadend|date=October 2009}} |
|||
| Verifiedfields = changed |
|||
'''Picoplatin''' is a cytotoxic platinum compound in clinical development by Poniard Pharmaceuticals, Inc. for the treatment of patients with solid tumors. |
|||
| Watchedfields = changed |
|||
| verifiedrevid = 444934628 |
|||
| ImageFile = Picoplatin.png |
|||
| ImageSize = 150px |
|||
| IUPACName = azane; 2-methylpyridine; platinum(2+); dichloride |
|||
| OtherNames = |
|||
|Section1={{Chembox Identifiers |
|||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = B5TAN0L720 |
|||
| CASNo_Ref = {{cascite|correct|??}} |
|||
| CASNo = 181630-15-9 |
|||
| PubChem = 177358 |
|||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|||
| ChemSpiderID = 154428 |
|||
| SMILES = Cc1ccccn1.N.[Cl-].[Cl-].[Pt+2] |
|||
| SMILES_Comment = ionic form |
|||
| SMILES1 = Cl[Pt-2](Cl)([NH3+])[n+]1ccccc1C |
|||
| SMILES1_Comment = coordination form |
|||
| InChI = 1/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2 |
|||
| InChIKey = IIMIOEBMYPRQGU-NUQVWONBAG |
|||
| StdInChI_Ref = {{stdinchicite|changed|chemspider}} |
|||
| StdInChI = 1S/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2 |
|||
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} |
|||
| StdInChIKey = IIMIOEBMYPRQGU-UHFFFAOYSA-L |
|||
}} |
|||
|Section2={{Chembox Properties |
|||
| C=6 | H=10 | Cl=2 | N=2 | Pt=1 |
|||
| Appearance = |
|||
| Density = |
|||
| MeltingPt = |
|||
| BoilingPt = |
|||
| Solubility = }} |
|||
|Section3={{Chembox Hazards |
|||
| MainHazards = |
|||
| FlashPt = |
|||
| AutoignitionPt = }} |
|||
}} |
|||
'''Picoplatin''' is a [[platinum-based antineoplastic agent]] in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid [[tumor]]s.<ref>{{cite journal | doi = 10.1039/C0DT00292E | volume=39 | title=The status of platinum anticancer drugs in the clinic and in clinical trials | year=2010 | journal=Dalton Transactions | last1 = Wheate | first1 = Nial J.| issue=35 | pages=8113–8127 | url=https://ses.library.usyd.edu.au/bitstream/2123/9269/2/41%20Dalton%20perspective.pdf | pmid=20593091 | hdl=2123/14271 | hdl-access=free }}</ref> |
|||
In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.<ref>[http://www.poniard.com/programs/picoplatin/clinical.html Picoplatin Clinical Results], Poniard Pharmaceuticals</ref> However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced [[small cell lung cancer]].<ref>[http://www.fiercebiotech.com/story/breaking-news-poniard-shares-crash-phiii-picoplatin-failure/2009-11-16 Poniard shares crash on Phase III picoplatin failure], fiercebiotech.com, November 16, 2009</ref> Hopes are now pinned on its use for metastatic [[colorectal cancer]].<ref>http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009</ref> |
|||
== References == |
== References == |
||
<!--- See [[Wikipedia:Footnotes]] on how to create references using <ref></ref> tags which will then appear here automatically --> |
|||
{{Reflist}} |
{{Reflist}} |
||
{{Platinum compounds}} |
|||
[[Category:Platinum(II) compounds]] |
|||
== External links == |
|||
[[Category:Organochlorides]] |
|||
* [http://www.poniard.com/ www.poniard.com] |
|||
[[Category:Pyridines]] |
|||
[[Category:Platinum-based antineoplastic agents]] |
|||
[[Category:Antineoplastic drugs]] |
|||
[[Category:Articles created via the Article Wizard]] |
|||
{{drug-stub}} |
{{antineoplastic-drug-stub}} |
||
Latest revision as of 17:10, 1 June 2022
| |
| Names | |
|---|---|
| IUPAC name
azane; 2-methylpyridine; platinum(2+); dichloride
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChemSpider | |
| ECHA InfoCard | 100.205.233 |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C6H10Cl2N2Pt | |
| Molar mass | 376.14 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid tumors.[1]
In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.[2] However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer.[3] Hopes are now pinned on its use for metastatic colorectal cancer.[4]
References
[edit]- ^ Wheate, Nial J. (2010). "The status of platinum anticancer drugs in the clinic and in clinical trials" (PDF). Dalton Transactions. 39 (35): 8113–8127. doi:10.1039/C0DT00292E. hdl:2123/14271. PMID 20593091.
- ^ Picoplatin Clinical Results, Poniard Pharmaceuticals
- ^ Poniard shares crash on Phase III picoplatin failure, fiercebiotech.com, November 16, 2009
- ^ http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |